A Villemain1, B Ribeiro Baptista2, N Paillot3, M Soudant4, O Menard2, Y Martinet5, A Tiotiu2. 1. Service d'oncologie médicale, groupe hospitalier Pitié-Salpêtrière, université Paris-VI, AP-HP, 47-83, boulevard de l'Hôpital, 75651 Paris cedex, France. Electronic address: villemainaurelie@gmail.com. 2. Département de pneumologie, CHRU de Nancy, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France. 3. Service de pneumologie, centre hospitalier et régional (CHR) de Metz-Thionville, 1, allée du Château, 57085 Ars-Laquenexy, France. 4. Inserm, CIC, épidémiologie clinique, CHRU de Nancy, université de Lorraine, 54000 Nancy, France. 5. Faculté de médecine, université de Lorraine, 54500 Vandoeuvre-lès-Nancy , France.
Abstract
INTRODUCTION: Skeletal-related events (SRE) are common in patients with bone metastatic lung cancer and have a negative impact on quality of life and survival. The objective of this study is to identify predictive factors for SRE occurrence among this population. METHODS: We conducted a 3-year retrospective study including 100 lung cancer patients with bone metastasis. RESULTS: Eighty-two patients presented at least one SRE (69.5% at baseline). The median occurrence for SRE was 4.5 months and severe bone pain was the most common SRE (56%). The alkaline phosphatase serum level>120IU/L (hazard ratio [sHR]=2.8; 95% confidence interval (CI) [1.5-5.4]; P=0.002) and calcemia>2.6mmol/L ([sHR]=9.7; 95% CI [5.1-18.4]; P<0.001) were identified as risk factors for SRE occurrence while the presence of an initial SRE was associated with a decrease of this risk ([sHR]=0.2; 95% CI [0.1-0.4]; P<0.001). CONCLUSION: The elevated alkaline phosphatase serum level and hypercalcemia are risk factors for SRE occurrence in bone metastatic lung cancer patients and should be used as biomarkers to adapt current medical practice for these patients.
INTRODUCTION: Skeletal-related events (SRE) are common in patients with bone metastatic lung cancer and have a negative impact on quality of life and survival. The objective of this study is to identify predictive factors for SRE occurrence among this population. METHODS: We conducted a 3-year retrospective study including 100 lung cancerpatients with bone metastasis. RESULTS: Eighty-two patients presented at least one SRE (69.5% at baseline). The median occurrence for SRE was 4.5 months and severe bone pain was the most common SRE (56%). The alkaline phosphatase serum level>120IU/L (hazard ratio [sHR]=2.8; 95% confidence interval (CI) [1.5-5.4]; P=0.002) and calcemia>2.6mmol/L ([sHR]=9.7; 95% CI [5.1-18.4]; P<0.001) were identified as risk factors for SRE occurrence while the presence of an initial SRE was associated with a decrease of this risk ([sHR]=0.2; 95% CI [0.1-0.4]; P<0.001). CONCLUSION: The elevated alkaline phosphatase serum level and hypercalcemia are risk factors for SRE occurrence in bone metastatic lung cancerpatients and should be used as biomarkers to adapt current medical practice for these patients.
Authors: Simin Liu; Ming Feng; Tingting Qiao; Haidong Cai; Kele Xu; Xiaqing Yu; Wen Jiang; Zhongwei Lv; Yin Wang; Dan Li Journal: Cancer Manag Res Date: 2022-01-03 Impact factor: 3.989